Drugs / ABBV-525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05618028 | Apr 2023 → Jul 2029 expected | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05618028 ↗ |
| Action | Inhibit | “ABBV-525 (MALT1 Inhibitor)” NCT05618028 ↗ |
| Route | Oral | “Oral; Tablet” NCT05618028 ↗ |